The Nifty Pharma index is strongly outperforming the frontline indices, with its ratio chart compared to Nifty reaching a 37-month high, highlighting its remarkable outperformance. According to Sudeep Shah, DVP and Head of Derivative and Technical Research at SBI Securities, The stock of Cipla Ltd has recently taken support in the zone of 1465-1475 and resumed its northward journey.
Read more at MoneycontrolAd
Ad